New York, Dec. 05, 2022 (GLOBE NEWSWIRE) -- The global mycobacterium tuberculosis treatment market was valued at US$ 1.97 Bn in 2021 and is expected to increase at a CAGR of 1.2% over the forecast period 2022-2032.
Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB), which mostly affects the lungs. Tuberculosis is a major public health crisis concern; however, it can be cured and prevented. Adults are most often affected by tuberculosis during their most productive years. Over 80% of cases and deaths occur in countries with low or middle incomes.
- According to WHO, tuberculosis is a major concern in every part of the world. WHO South-East Asian Region had 46% of new TB cases in 2021, followed by WHO African Region with 23% and WHO Western Pacific with 18% of new cases.
Rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing nations, as well as a growing initiative by government organizations for tuberculosis awareness, are some of the factors that are driving the expansion of the market.
- A new consortium of 30 partners from 13 countries was officially launched in July 2021 to advance anti-tuberculosis (TB) science and facilitate the development of new, safe, and affordable treatment options for TB patients all over the world. The 7-year, €185 million project called UNITE4TB, means to speed up and work on the clinical assessment of existing and novel medications, determined to foster new and dynamic TB treatment regimens for drug-safe and sensitive TB.
- The Innovative Medicines Initiative (IMI) Antimicrobial Resistance (AMR) Accelerator's newest project, UNITE4TB, is a public-private partnership whose objective is to advance the development of new drugs to treat or prevent infectious diseases, including tuberculosis.
“Rising awareness of the prevention of tuberculosis and growing demand for multi-drug resistant (MDR) drugs will drive market growth,” says an analyst of Persistence Market Research.
Request for sample copy of report: https://www.persistencemarketresearch.com/samples/33190
Key Takeaways from Market Study
- Active TB held more than 68% market share by disease type in 2021.
- First-line of drugs held 74.5% share of the global mycobacterium tuberculosis treatment market in 2021.
- Oral route of administration accounted for a market share of 63.4% in 2021.
- By distribution channel, hospital pharmacies are widely preferred for tuberculosis drugs and the segment held a market share of 35.6% in 2021.
- In 2021, South Asia held the largest market share of 29.7%.
Know the methodology of report: https://www.persistencemarketresearch.com/methodology/33190
Market Competition
Companies manufacturing mycobacterium tuberculosis medications are actively working toward strengthening their current market position and maintaining their market share by partnering with other competent players or by speeding up the process of clinical trials for pipeline drugs.
- In March 2022, Bharat Biotech entered into a partnership with Biofabri for the manufacturing, development, and marketing of a new tuberculosis vaccine. This partnership agreed to the supply of tuberculosis (TB) vaccines in more than 70 countries, especially in sub-Saharan Africa and Southeast Asia.
- In January 2022, GlaxoSmithKline updated the trial of its drug - GSK-3036656 to 'completed' for the treatment of pulmonary tuberculosis.
Get full access of report: https://www.persistencemarketresearch.com/checkout/33190
Want to Know More?
Persistence Market Research, a research and consulting firm, has published a revised market research report on the electric cargo bike market that contains a global industry analysis of 2017–2021 and an opportunity assessment for 2022–2032. The report provides in-depth analysis of the market through different segments, namely, product type, battery type, end use, and region.
Other Trending Reports:
About Persistence Market Research:
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.
Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.
Contact
Rajendra Singh
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
